Sign in
Taking people in United StatesPhase 4

Risedronate for hearing loss in adults with osteogenesis imperfecta

Tests risedronate for hearing loss in adults with osteogenesis imperfecta.

Key facts

Who runs it
Hospital for Special Surgery, New York
Where
New York, United StatesSee the site
Trial code
Registry title
Effects of Bisphosphonates on OI-Related Hearing Loss
Status
Recruiting
Phase
Phase 4
People taking part
100 people, planned
Started
2 Nov 2019
Expected to end
Jan 2027
Type of study
Interventional, 4 groupsOne group gets no study treatment, for comparison.
Treatments tested
  • Risedronate Oral Tablet
Record updated
28 April 2026

Who can take part

AI summary

From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.

The trial is looking for people with osteogenesis imperfecta (OI, brittle bone disease). Adults with OI type I can join a treatment group or a control group. Children aged 6-17 with any type of OI can join observation groups.

Age
6 to 100 years. Adults are 18 or older. Children are 6-17 years.
Sex
All sexes can join.
Disease stage
Adults: OI type I. The adult treatment group also needs at least mild hearing loss (>20dB pure tone average) on a hearing test (audiogram). Children: any type of OI.
Earlier treatment
Children in one group must already get bisphosphonate treatment as standard care. Children in the other group must not get bisphosphonate treatment, now or during the study.
Biomarker or test result
Adult treatment group: vitamin D level > 30.

Main reasons for not taking part

  • Family history of hearing loss not caused by OI or by noise at work
  • Pregnancy

The registry criteria, word for word

Show all 13 criteriaShow less

Who can take part

  • Diagnosis of OI type I
  • Diagnosis of at least mild hearing loss (>20dB pure tone average) by audiogram testing
  • 18+
  • Vitamin D level > 30
  • Diagnosis of OI type I
  • Diagnosis of OI
  • Age 6-17 years
  • Currently receiving bisphosphonate treatment as standard of care
  • Diagnosis of OI
  • Age 6-17 years
  • NOT receiving bisphosphonate treatment and will not receive bisphosphonate treatment for the duration of the study

Who cannot take part

  • Family history of hearing-loss (not related to OI or occupational hearing loss)
  • Pregnancy

Check if you might fit

Answer for yourself. This is not a decision: only the study team can say whether you can take part.

  • Are you between 6 and 100 years old?

Where in United States

  • Hospital for Special SurgeryNew York, United StatesContact: Su HtweTaking people

About the trial

What the trial wants to find out

Osteogenesis Imperfecta-related hearing loss usually occurs in individuals with mild (type I) OI and is much earlier in onset than age-related hearing loss, with the majority of individuals experiencing some minor hearing loss in their 20s. Bisphosphonates have been successfully used to treat otosclerosis, a common cause of hearing loss similar to OI-related hearing loss. As many individuals with OI-related hearing loss also present with otosclerosis and because of their mechanistic similarities, the investigators propose studying the effects of bisphosphonate treatment on individuals diagnosed with both OI type I and hearing loss, thereby determining its effectiveness as a potential treatment for hearing loss.

Read full original descriptionShow less

The investigators will enroll 50 individuals diagnosed with type I OI and age 18-100. 25 adults will be enrolled into the treatment arm and receive bisphosphonate treatment (must have at least mild hearing loss), while 25 adults will be enrolled into the control arm. The investigators will enroll 25 children (6-17 years of age) diagnosed with OI who are currently receiving bisphosphonate treatment as part of their care for orthopedic symptoms. The investigators will also observe 25 children (6-17 years of age) diagnosed with OI who are NOT currently receiving bisphosphonate treatment. The study duration is 63 months (approximately 5 years). Enrollment is anticipated to begin in November 2019.

The 4 groups in the trial

  • Adult Treatment ArmTreatment being tested

    Intervention treatment arm. Adults (18+ years) with type 1 OI. Must have at least mild hearing loss. Will receive Risedronate (35mg, 0-2x/week as clinically indicated) for duration of study. Changes in hearing, quality of life, and bone density will be monitored.

    Treatment: Risedronate Oral Tablet

  • Child (Bisphosphonate Arm)No study treatment, for comparison

    Observational (no investigational intervention) arm. Children (6-17 years) with any type of OI who are already receiving bisphosphonate treatment as standard of care treatment for orthopedic symptoms. Changes in hearing, quality of life, and bone density will be observed for the duration of the study.

  • Child (Control Arm)No study treatment, for comparison

    Observational arm. Children (6-17 years) with any type of OI who are not receiving bisphosphonate treatment. Changes in hearing, quality of life, and bone density will be observed for the duration of the study.

  • Adult Control ArmNo study treatment, for comparison

    Observational arm. Adults (18+ years) with type 1 OI. Changes in hearing, quality of life, and bone density will be monitored.

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record → Contacts and Locations

Print a page for my doctor

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Official title
Effects of Bisphosphonates on OI-Related Hearing Loss: A Pilot Study
Plain-language title
Risedronate for hearing loss in adults with osteogenesis imperfectaGenerated from the registry record. The registry title is the official one.
AI summary
From the trial's eligibility criteria. Read by machine on 14 November 2026.
Fit questions
Built from NCT04152551, who can take part
Record updated
28 April 2026